Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

308 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based "Triple Therapy" Experience in Southern Italy.
Morisco F, Masarone M, Rosato V, Camera S, Granata R, Tartaglione MT, Coppola C, Coppola N, Salomone-Megna A, Gentile I, De Luna A, Federico A, Precone D, Claar E, Abenavoli L, Persico M. Morisco F, et al. Among authors: coppola n, coppola c. Rev Recent Clin Trials. 2016;11(4):306-316. doi: 10.2174/1574887111666151217123222. Rev Recent Clin Trials. 2016. PMID: 26672601
Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania.
Guarino M, Tortora R, de Stefano G, Coppola C, Morisco F, Salomone Megna A, Izzo F, Nardone G, Piai G, Adinolfi LE, D'Adamo G, Gaeta GB, Messina V, Francica G, De Girolamo V, Coppola N, Persico M, Di Costanzo GG; Progetto Epatocarcinoma Campania Group. Guarino M, et al. Among authors: coppola n, coppola c. J Gastroenterol Hepatol. 2018 May;33(5):1123-1130. doi: 10.1111/jgh.14013. Epub 2018 Feb 7. J Gastroenterol Hepatol. 2018. PMID: 28994145
Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort).
Gentile I, Scotto R, Coppola C, Staiano L, Amoruso DC, De Simone T, Portunato F, De Pascalis S, Martini S, Macera M, Viceconte G, Tosone G, Buonomo AR, Borgia G, Coppola N. Gentile I, et al. Among authors: coppola n, coppola c. Hepatol Int. 2019 Jan;13(1):66-74. doi: 10.1007/s12072-018-9914-6. Epub 2018 Dec 6. Hepatol Int. 2019. PMID: 30523552
Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment.
Pisaturo M, Starace M, Minichini C, De Pascalis S, Macera M, Occhiello L, Messina V, Sangiovanni V, Claar E, Precone D, Stornaiuolo G, Stanzione M, Gentile I, Brancaccio G, Martini S, Masiello A, Megna AS, Coppola C, Federico A, Sagnelli E, Persico M, Lanza AG, Marrone A, Gaeta GB, Coppola N. Pisaturo M, et al. Among authors: coppola n, coppola c. Antivir Ther. 2019;24(7):485-493. doi: 10.3851/IMP3296. Antivir Ther. 2019. PMID: 30758299
Efficacy of the "first wave" Direct Acting antivirals against HCV infection: results from the Italian LINA (Liver Network Activity) cohort.
Gentile I, Buonomo AR, Coppola C, Staiano L, Amoruso DC, Saturnino MR, Maraolo AE, Portunato F, De Pascalis S, Martini S, Crispo M, Macera M, Pinchera B, Zappulo E, Scotto R, Coppola N. Gentile I, et al. Among authors: coppola n, coppola c. New Microbiol. 2019 Apr;42(2):94-100. Epub 2019 Apr 29. New Microbiol. 2019. PMID: 31034085 Free article.
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study.
Persico M, Aglitti A, Milella M, Coppola C, Messina V, Claar E, Gentile I, Sogari F, Pierri P, Surace LA, Morisco F, Tundo P, Brancaccio G, Serviddio G, Gatti P, Termite AP, Di Costanzo GG, Caroleo B, Cozzolongo R, Coppola N, Longo A, Fontanella L, Federico A, Rosato V, Terrenato I, Masarone M. Persico M, et al. Among authors: coppola n, coppola c. Liver Int. 2019 Oct;39(10):1852-1859. doi: 10.1111/liv.14170. Epub 2019 Jul 2. Liver Int. 2019. PMID: 31175707
Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study.
Adinolfi LE, Petta S, Fracanzani AL, Coppola C, Narciso V, Nevola R, Rinaldi L, Calvaruso V, Staiano L, Di Marco V, Marrone A, Pafundi PC, Solano A, Lombardi R, Sasso FC, Saturnino M, Rini F, Guerrera B, Troina G, Giordano M, Craxì A. Adinolfi LE, et al. Among authors: coppola c. Atherosclerosis. 2020 Mar;296:40-47. doi: 10.1016/j.atherosclerosis.2020.01.010. Epub 2020 Jan 21. Atherosclerosis. 2020. PMID: 32005004 Clinical Trial.
Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort).
Buonomo AR, Scotto R, Coppola C, Pinchera B, Viceconte G, Rapillo CM, Staiano L, Saturnino M, Scarano F, Portunato F, Pisaturo M, De Pascalis S, Martini S, Tosone G, Nappa S, Coppola N, Gentile I. Buonomo AR, et al. Among authors: coppola n, coppola c. Medicine (Baltimore). 2020 Feb;99(6):e18948. doi: 10.1097/MD.0000000000018948. Medicine (Baltimore). 2020. PMID: 32028404 Free PMC article.
308 results